EP0617618A1 - Aryltriflate und verwandte verbindungen - Google Patents

Aryltriflate und verwandte verbindungen

Info

Publication number
EP0617618A1
EP0617618A1 EP93901666A EP93901666A EP0617618A1 EP 0617618 A1 EP0617618 A1 EP 0617618A1 EP 93901666 A EP93901666 A EP 93901666A EP 93901666 A EP93901666 A EP 93901666A EP 0617618 A1 EP0617618 A1 EP 0617618A1
Authority
EP
European Patent Office
Prior art keywords
substituted
compound
compounds
mmol
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93901666A
Other languages
English (en)
French (fr)
Inventor
Hakan Vilhelm Wikström
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of EP0617618A1 publication Critical patent/EP0617618A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/28Morphinans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00Inks
    • C09D11/30Inkjet printing inks
    • C09D11/32Inkjet printing inks characterised by colouring agents
    • C09D11/324Inkjet printing inks characterised by colouring agents containing carbon black
    • C09D11/326Inkjet printing inks characterised by colouring agents containing carbon black characterised by the pigment dispersant

Definitions

  • the present invention is directed toward new aryltriflates, and their pharmaceuti ⁇ cally acceptable salts, to processes for preparing such compounds, pharmaceutical preparations of such compounds and the use of such compounds in manufacture of a pharmaceutical preparation.
  • Pharmaceutical preparations of these compounds are useful for peripheral and central nervous system disorders in mammals.
  • Aryl triflates are used as intermediates in organic syntheses. They can thus be removed via reduction (NEt 3 +HCOO-) or substituted by other groups like CN and COOR (Oda, R., Kagaku (Kyoto) 1987, 42, 710-11 ; Cacchi, S. et al., Tetrahedron Lett 1986, 27, 5541-4; Chambers, M. R. I. et al., J. Chem. Soc, Perkin Trans 1989, 1, 1365-6; Kotsuki, H. et al., Synthesis 1990; Martorell, G. et al., Tetrahedron Lett
  • Enzymatic deactivation of drugs is a well known phenomenon, in particular phenols and methoxylated aryls are in general easily oxidized in the liver and elsewhere where these enzyme systems are active (e. g. the gastric mucosa and the lungs). Inactivation of phenols can take place via direct conjugation (sulphation and glucoronidation) and/or via initial oxidation and then conjugation.
  • the inhibition of such enzymatic deactivation of drugs is highly desired, and the object of the present invention is to provide therapeutically effective drugs having a low liability for enzymatic deactivation.
  • drugs with better pharmacokinetic properties than the corresponding hydroxy and/or alkoxy substi ⁇ tuted analogues are particularly preferred.
  • triflate derivatives of drugs comprising a hydroxyaryl group or a similar group possess both good pharmacodynamic and good pharmaco ⁇ kinetic properties including a high resitance against enzymatic deactivation.
  • This invention relates to aryltriflates and related compounds having the general Formula 1 :
  • Formula 1 or pharmaceutically acceptable acid addition salts thereof wherein Ar is an aromatic or heteroaromatic system of a compound which has a therapeutic, biological activity when it, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group; and Ri is CF 3 , (C Cs) alkyl, -CH 2 -(C 3 -C ⁇ ) cycloalkylalkyl, substituted phenyl, substi ⁇ tuted benzyl, substituted phenylethyl, substituted phenylpropyl, substituted 2-thio ⁇ phenylethyl or substituted 2-thiophenylpropyl; except the compounds wherein Ar is 2-(dipropylamino)-tetralin-8-yl or 4- acetamidophenyl.
  • the invention is directed to compounds of Formula 1 ; wherein Ri is CF 3 .
  • (C n -C m ) is inclusive such that a compound of (C C ⁇ ) would include compounds of one to 8 carbons and their isomeric forms.
  • Alkyl refers to an branched or unbranched aliphatic hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pen- tyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, and n-octyl.
  • Halogen means fluoro, chloro, bromo or iodo.
  • Compounds which has a therapeutic, biological activity when they, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group may be any therapeutical effective compounds comprising an aryl group carrying such a substituent.
  • the compound is a drug acting in the central nervous system, in particular a dopamine agonist or antagonist, a dopamine autoreceptor agonist, a 5- HTIA ligand, 5-HTID ligand, a 5-HT 2 antagonist, an antipsychotic, a sigma ligand, or a melatonine analogue, beta blocker, analgesic, etc.
  • R_ is as defined above;
  • R2 designates C Cs alkyl, CH 2 -(C3-C8) cycloalkylalkyl, arylalkyl, phenylethyl or 2-thiophenylethyl;
  • R3 designates C Cs alkyl, CH2-(C3-Cs) cycloalkylalkyl, arylalkyl, phenylethyl or 2-thiophenylethyl;
  • X is CH 2 , O or S; and
  • Y is CH 2 , O or S.
  • R 2 and R 3 are not at the same time propyl
  • the pharmaceutically acceptable acid addition salts of the compounds may be for ⁇ med by reaction with non-toxic organic or inorganic acids in an aqueous miscible solvent, such as acetone or ethanol, and subsequent isolation of the salt by concen ⁇ tration and cooling or by reaction with an excess of the acid in aqueous immiscible 5 solvent, such as ethyl ether or chloroform, with the desired salt separating directly.
  • an aqueous miscible solvent such as acetone or ethanol
  • organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis methylene-salicylic, methanesulfonic, ethane- disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, o cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as the 8- halotheophyllines, for example 8-bromo-theophylline.
  • inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
  • these salts may also be prepared by the classical method of 5 double decomposition of appropriate salts, which is well known to the art.
  • the compounds of the present invention will normally be adminis ⁇ tered orally, rectally or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or as a pharmaceutically 0 acceptable non-toxic, acid addition salt, such as the hydrochloride, lactate, acetate, sulfamate salt, in association with a pharmaceutically acceptable carrier.
  • a pharmaceutically 0 acceptable non-toxic, acid addition salt such as the hydrochloride, lactate, acetate, sulfamate salt
  • the suitable daily doses of the compounds of the invention are from about 1 mg to 2000 mg for oral application, preferentially 50-500 mg, and 0.1 to about 100 mg for parenteral application, preferentially 0.5-50 mg daily doses.
  • the daily dose will preferably be administered in individual dosages one to 4 times daily and the dosage amounts are based on an individual having a o weight of 70 kg.
  • the compounds of this invention have high oral potency and long duration of action, as compared to their hydroxy or alkoxy analogues. Both these pharmacokinetic features are beneficial to effective clinical treatment.
  • the triflating agent is conveniently triflic anhydride (Method A), N-phenyltrifluoro- methanesulfonimide (Method B) or triflic acid chloride (Method C).
  • trans-racemic 82172-01-8 trans-4aS,10bS: 131484-03-2 r trans-4aR,10bR: 131484-02-1 cis-racemic: 82172-00-7 cis-4aR,10bS: 109062-23-9 cis-4aS,10bR: 109062-21-7
  • the electronegativity of the OTf group is indicated by the downfield shift of the aromatic protons from 6.3-6.9 in the starting material (8-OH-2-(acetamido)tetralin) to 7.0-7.3 in the triflated product (with respect to the electronic effects of the triflate group, see also ref: Stang, P. and Anderson, A. G., J. Org. Chem. 1976, 41 , 781 ).
  • N-phenyltrifluoromethanesulfonimide [RN 37595-74-7; from Aldrich] (75 mg; 0.21 mmol) was added in one portion at room temperature.
  • the reaction mixture was monitored with GC and TLC, and after 20 h all starting material was consumed.
  • the solvent and the Et 3 N were evaporated and the remaining oil was dissolved in ether (10 mL) and washed 3 times with NaCI saturated water, separated and dried ( gS ⁇ 4 ).
  • the solvent was evaporated and the remaining oil was dissolved in EtOH (5 mL) and fumaric acid (0.23 g, 0.20 mmol) dissolved in EtOH (1 mL) was added and the solvent was evaporated.
  • the remaining solid was recrystaliized from i-propylacetate.
  • Example 6 11-Hydroxy-10-trifluoromethyl(sulfonyl)oxy-aporphine.
  • 3-Trifluoromethansulfonyloxy-morphine (fumarate salt) 100 mg; 0.19 mmol was stirred for 3 hrs at 105 °C in MeSOsH (5 mL) under N 2 -atmosphere.
  • the reaction mixture was allowed to cool to room temperature and was then diluted with H2O (10 mL).
  • the aquous layer was basified with NaHC03 (s) and then extracted with CH2CI2 (3x25 mL).
  • the organic layers were combined, dried over Na 2 S ⁇ 4 , filtered and evaporated in vacuo.
  • Dextrorphan tartaric acid salt (1 :1) (1.0 g; 2.46 mmol) was suspended in CH 2 CI 2 5 (100 mL) and Et 3 N (2 mL; 14 mmol) was added and the solution was stirred until all the starting material had dissolved. Then the mild, triflating agent N-phenyltrifluoro- methanesulfonimide [RN 37595-74-7; from Aldrich] (1.05 g; 2.94 mmol) was added in one portion. The reaction mixture was monitored with GC and after 4 h all dextrorphan was consumed. The solvent and the Et 3 N were evaporated and the
  • the base was converted to its hydrochloride salt with HCI saturated ether.
  • the IR spectrum shows strong absorption bands at: 3000, 1460, 1420, 1210 and 1140 cm -1.
  • This test is a test for the DA Di receptor antagonistic effect in vivo.
  • the experiments are performed as described by Arnt, J.et al., J. Neural. Transm. 1986, 67, 225-240.
  • the test is a test for 5-HT 2 -antagonistic effect testing the ability to inhibit quipazine induced head twitches.
  • the method and test results for some reference substances are published by Arnt et al. (Drug Development Research, 16, 59-70, 1989). Dopamine agonist studies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP93901666A 1991-12-18 1992-12-18 Aryltriflate und verwandte verbindungen Withdrawn EP0617618A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9103745A SE9103745D0 (sv) 1991-12-18 1991-12-18 Aryl-triflates and related compounds
SE9103745 1991-12-18
PCT/DK1992/000389 WO1993011761A1 (en) 1991-12-18 1992-12-18 Aryl-triflates and related compounds

Publications (1)

Publication Number Publication Date
EP0617618A1 true EP0617618A1 (de) 1994-10-05

Family

ID=20384643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901666A Withdrawn EP0617618A1 (de) 1991-12-18 1992-12-18 Aryltriflate und verwandte verbindungen

Country Status (8)

Country Link
EP (1) EP0617618A1 (de)
JP (1) JPH08504744A (de)
AU (1) AU3255993A (de)
CA (1) CA2126242A1 (de)
FI (1) FI942931A (de)
NO (1) NO942296D0 (de)
SE (1) SE9103745D0 (de)
WO (1) WO1993011761A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4340437B2 (ja) 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート 8−カルボキサミド−2,6−メタノ−3−ベンズアゾシン
NZ527815A (en) 2001-03-29 2005-05-27 Lilly Co Eli N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
WO2003072055A2 (en) * 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CA2692440A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
JP5691042B2 (ja) 2009-12-04 2015-04-01 アルカーメス ファーマ アイルランド リミテッド 薬物過量摂取の治療のためのモルヒナン誘導体
EP2550253B9 (de) 2010-03-22 2016-09-21 Rensselaer Polytechnic Institute Carboxamid-bioisostere von opiaten
RS65091B1 (sr) 2010-08-23 2024-02-29 Alkermes Pharma Ireland Ltd Postupci za lečenje povećanja telesne težine indukovanog antipsihoticima
US9029543B2 (en) 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
EP2725908B1 (de) 2011-06-29 2017-05-31 Alkermes, Inc. Peripher wirkende opioidverbindungen
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP6038170B2 (ja) 2011-12-15 2016-12-07 アルカーメス ファーマ アイルランド リミテッド ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
EP3003311A2 (de) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Verfahren zur behandlung von symptomen für depression
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
EP4243768A1 (de) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Mehrschichttablette mit sofortiger freisetzung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725451A (en) * 1970-04-13 1973-04-03 Riker Laboratories Inc Substituted benzoylhaloalkanesulfonanilides
DE3132167A1 (de) * 1981-08-14 1983-03-03 Hoechst Ag, 6000 Frankfurt "5(6)-phenylsulfonyloxy-benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung gegen leberegel"
DE3232959A1 (de) * 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3243158A1 (de) * 1982-11-23 1984-05-24 Basf Ag, 6700 Ludwigshafen Neue sulfonsaeureester von hydroxycumarinen, ihre herstellung und sie enthaltende arzneimittel
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4470991A (en) * 1983-04-22 1984-09-11 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
FR2557570B1 (fr) * 1984-01-04 1986-04-18 Adir Nouveaux derives de la quinoleine, leur procede de preparation et les compositions pharmaceutiques les renfermant
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
DE3521761A1 (de) * 1985-06-19 1987-01-02 Bayer Ag Neue 1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3630903A1 (de) * 1986-09-11 1988-03-24 Thomae Gmbh Dr K Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
GB8804016D0 (en) * 1988-02-22 1988-03-23 Boots Co Plc Therapeutic agents
DE3807813A1 (de) * 1988-03-10 1989-09-21 Thomae Gmbh Dr K Neue benzocycloheptenderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
KR920004385A (ko) * 1990-08-09 1992-03-27 와꾸나가 기스께 신규 삼환화합물 또는 그의 염, 이의 제조방법 및 이를 함유하는 항균제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9311761A1 *

Also Published As

Publication number Publication date
CA2126242A1 (en) 1993-06-24
WO1993011761A1 (en) 1993-06-24
FI942931A0 (fi) 1994-06-17
SE9103745D0 (sv) 1991-12-18
NO942296L (no) 1994-06-17
NO942296D0 (no) 1994-06-17
AU3255993A (en) 1993-07-19
JPH08504744A (ja) 1996-05-21
FI942931A (fi) 1994-06-17

Similar Documents

Publication Publication Date Title
EP0617618A1 (de) Aryltriflate und verwandte verbindungen
FR2567885A1 (fr) Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant
EP0373998B1 (de) Propenonoximether, Verfahren zu dessen Herstellung sowie diese enthaltende Arzneinmittel
LU81453A1 (fr) Nouveaux derives de l'indole,leur preparation et leur application comme medicaments
JP2750187B2 (ja) 治療上有効なテトラリン誘導体
KR100193981B1 (ko) 신규한 8-치환-2-아미노테트랄린
WO2005118547A1 (fr) Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique
KR900003883B1 (ko) 3,4-디하이드로-2h-[ 1 ]-(벤조피란 및 벤조 티오피란)-3-아민 및 이의 제조방법
EP1096926B1 (de) Verfahren und verbindungen zur behandlung der depression
EP1057826A1 (de) Substituierte dimere Carboxamid-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
FR2548666A1 (fr) Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique
EP1828125B1 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden
JPH02744A (ja) 心臟血管系に対し活性な化合物
EP0620221A1 (de) 5-Acylamino-1,2,4-Thiadiazole als cholecystokin Antagonisten oder Agonisten
EP0452204B1 (de) 3-Aminochroman-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EP0998471B1 (de) Heterozyclische verbindungen, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
EP1466604B1 (de) Isochinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung um Melatonin System-Probleme zu behandeln
EP0053964A1 (de) 1(4-Chinolyl)äthanol- bzw. -propanolderivate, diese enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0382618B1 (de) Aminoalkoxyphenyl-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen
EP0135489B1 (de) Benzofuranderivate, ihre Herstellung und ihre therapeutische Verwendung
FR2462438A1 (fr) Nouveaux derives de la 6-alkyl-7-phenyl-1,6-naphtyridine-5(6h)-one, leur preparation et leur application comme medicaments
EP1224182B1 (de) N-substituierte 1-(butyrolacton)-isochinoline zur behandlung von nervenstörungen
CA2031839A1 (fr) Derives de la piperidine, leur procede de preparation et les compositions pharmaceutiques les renfermant
JPH06507906A (ja) カルボキサミド−(3,2n)−カルボサイクリック−2−アミノテトラリン誘導体
CA2309771C (fr) Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: H. LUNDBECK A/S

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WIKSTROEM, HAKAN VILHELM

17Q First examination report despatched

Effective date: 19960701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19961112